Insights

On 13 February 2026, the International Council for Harmonisation (ICH) published the “Sakura Bloom R2” mock example, developed by the M4Q(R2) Expert Working Group to illustrate the revised structure and presentation of CTD Quality Modules 2.3 and 3 under the draft ICH M4Q(R2) guideline. While explicitly non‑binding and intended for illustration purposes only, the example offers a concrete glimpse into how quality dossiers are expected to evolve in the coming years.

M4Q(R2) is not merely a reorganization of existing content. It represents a shift in regulatory expectations — from compiling information into static sections to telling a coherent, structured quality story supported by evidence. Quality information is no longer just presented; it is explained, contextualized, and connected.

For pharmaceutical companies, this evolution means that future readiness will depend not only on the robustness of the data generated, but also on the ability to clearly articulate development rationale, product understanding, and control strategies throughout the dossier lifecycle.

Regulatory Pharma Net supports pharmaceutical companies in interpreting and implementing the M4Q(R2) vision, helping transform traditional quality documentation into integrated regulatory narratives that reflect modern ICH quality principles. By bridging evolving guidelines with practical dossier execution, we help ensure submissions remain compliant, credible, and inspection‑ready in an increasingly dynamic regulatory landscape.

Contact us at info@rpngroup.com